Updated from 2:01 p.m. EDTHealth stocks dominated small-cap movers Tuesday, and leading the way was Adolor (ADLR), plummeting more than 58% after a late-phase study of alvimopan, a gastrointestinal treatment, induced higher (but statistically insignificant) rates of adverse cardiovascular events and cases of skin lesions than a placebo. Adolor's partner, GlaxoSmithKline (GSK - Get Report), halted other studies involving the compound. Adolor shares closed down $5.12 to $3.60. GlaxoSmithKline shares gave up 17 cents to $55.95.
Tuesday's Small-Cap Winners & Losers
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.